Zusammenfassung
Diuretika werden zur Behandlung von Krankheiten eingesetzt, bei denen das therapeutische Ziel die Verminderung des Extrazellulärvolumens durch Vermehrung der Ausscheidung von Salz und Wasser ist. Hauptindikationen sind arterielle Hypertonie, Herzinsuffizienz sowie Ödeme kardialer, hepatischer und renaler Genese.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Buggey J, Mentz RJ, Pitt B, Eisenstein EI, Anstrom KJ, Velazquez EJ, O’Connor CM (2015): A reappraisal of loop diuretic choice in heart failure patients. Am Heart J 169: 323–333
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003): The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560–2571
Cosin J, Diez J, TORIC investigators (2002): Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4: 507–513
Düsing R, Piesche L (1990): Second line therapy of congestive heart failure with torasemide. Prog Pharmacol Clin Pharmacol 8: 105–120
Gentilini P, Laffi G, La Villa G, Carloni V, Foschi M, Romanelli RG, Marra F (1993): Torasemide in the treatment of patients with cirrhosis and ascites. Cardiovasc Drugs Ther 7 (Suppl 1): 81–85
Jacob MS, Tang WH (2011): Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. Curr Heart Fail Rep. 8: 7–13
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004): Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543–551
Lachaine J, Beauchemin C, Ramos E (2011): Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clin Pharmacol May 20; 11: 4. doi: 10.1186/1472-6904-11-4
Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM et al (2001): Open label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 111: 513–520
Oßwald H, Vallon V, Luippold G, Gleiter CH (2004): Diuretika – Physiologie, Pharmakologie und klinische Anwendungen. Wissenschaftliche Verlagsgesellschaft, Stuttgart
Pitt B, Nicklas J (2009): Loop diuretics in patients with heart failure: time to change to torsemide? J Cardiovasc Pharmacol 53: 435–437
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003): Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999): The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717
Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS (2003): Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289: 2534–2544
Roush GC, Holford TR, Guddati AK (2012): Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network metaanalyses. Hypertension 59: 1110–1117
Roush GC, Kaur R, Ernst ME (2014): Diuretics: a review and update. J Cardiovasc Pharmacol Ther 19: 5–13
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2003): Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997
The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013): 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 31: 1281–1357
Wargo KA, Banta WM (2009): A comprehensive review of the loop diuretics: Should furosemide be first line? Ann Pharmacother 43: 1836–1847
Wilcox CS (2002): New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13: 798–805
Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL (2006): Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48: 219–224
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Oßwald, H., Mühlbauer, B. (2018). Diuretika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2018. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57386-0_26
Download citation
DOI: https://doi.org/10.1007/978-3-662-57386-0_26
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57385-3
Online ISBN: 978-3-662-57386-0
eBook Packages: Medicine (German Language)